ReviewImmunology2009
Tricks with tetramers: how to get the most from multimeric peptide-MHC.
Review in Immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 108 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
108 citing papers in PubMed, 181 citations in OpenAlex.
- α2,6-Sialoglycan-regulated antitumor immunity of tumor-infiltrating CD8Nature chemical biology · 2026Article
- HLA-E-restricted T cells primed by a modified HLA-B*57:01-restricted HIV-1 peptide suppress HIV-1 replication.JCI insight · 2026Article
- A cell-based kinetic framework enables TCR specificity prediction.Signal transduction and targeted therapy · 2026Article
- Mechanotransduction through T cell receptors: consensus, controversies and future outlooks.Experimental & molecular medicine · 2026Review
- Design of solubly expressed miniaturized SMART MHCs.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Optimized procurement of cancer-reactive T-cell receptors from clinical samples.Immunotherapy advances · 2026Article
- Article
- Utilizing pMHC Multimers to Study Antigen-Specific T Cells and T Cell Exhaustion in Chronic Viral Infections.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Citrullinated Autoantigen-Specific T and B Lymphocytes in Rheumatoid Arthritis: Focus on Follicular T Helper Cells and Expansion by Coculture.ACR open rheumatology · 2025Article
- CRISPR-Cas9 screening reveals a distinct class of MHC-I binders with precise HLA-peptide recognition.iScience · 2024Article
- Harnessing T cell exhaustion and trogocytosis to isolate patient-derived tumor-specific TCR.Science advances · 2023Article
- Antigen-Specific CD4 T Cell and B Cell Responses to Borrelia burgdorferi.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- Reactivation of low avidity tumor-specific CD8Journal for immunotherapy of cancer · 2023Article
- Screening self-peptides for recognition by mouse alloreactive CD8STAR protocols · 2023Article
- The superantigens SpeC and TSST-1 specifically activate TRBV12-3/12-4Communications biology · 2023Article
- Antigen-specificity measurements are the key to understanding T cell responses.Frontiers in immunology · 2023Review
- Utilizing immunogenomic approaches to prioritize targetable neoantigens for personalized cancer immunotherapy.Frontiers in immunology · 2023Review
- Multivalent binding kinetics resolved by fluorescence proximity sensing.Communications biology · 2022Article
- Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma.Nature communications · 2022Article
- CD8 coreceptor engagement of MR1 enhances antigen responsiveness by human MAIT and other MR1-reactive T cells.The Journal of experimental medicine · 2022Article
48 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of fluorochrome-conjugated peptide-major histocompatibility complex (pMHC) multimers in conjunction with continuing advances in flow cytometry has transformed the study of antigen-specific T cells by enabling their visualization, enumeration, phenotypic characterization and isolation from ex vivo samples. Here, we bring together and discuss some of the 'tricks' that can be used to get the most out of pMHC multimers. These include: (1) simple procedures that can substantially enhance the staining intensity of cognate T cells with pMHC multimers; (2) the use of pMHC multimers to stain T cells with very-low-affinity T-cell receptor (TCR)/pMHC interactions, such as those that typically predominate in tumour-specific responses; and (3) the physical grading and clonotypic dissection of antigen-specific T cells based on the affinity of their cognate TCR using mutant pMHC multimers in conjunction with new approaches to the molecular analysis of TCR gene expression. We also examine how soluble pMHC can be used to examine T-cell activation, manipulate T-cell responses and study allogeneic and superantigen interactions with TCRs. Finally, we discuss the problems that arise with pMHC class II (pMHCII) multimers because of the low affinity of TCR/pMHCII interactions and lack of 'coreceptor help'.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.